Neurocrine Biosciences (NBIX) EBT Margin (2010 - 2026)

Neurocrine Biosciences has reported EBT Margin for 16 years, with the latest figure at 30.3% in Q1 2026.

• For the quarter ending Q1 2026, EBT Margin rose 2773.0% year-over-year to 30.3%; the trailing twelve-month figure through Mar 2026 stood at 30.22% (up 1089.0% YoY), and the FY2025 full-year result was 24.66%, up 403.0% from the prior year.
• EBT Margin for Q1 2026 stood at 30.3%, up from 29.72% in the prior quarter.
• The five-year high for EBT Margin was 38.47% in Q4 2023, with the low at 116.5% in Q2 2022.
• Historically, EBT Margin has averaged 12.39% across 5 years, with a median of 25.24% in 2022.
• Annual changes were most pronounced in 2022 — EBT Margin slumped 13640 bps — and 2023, when it jumped 14336 bps.
• Neurocrine Biosciences' EBT Margin stood at 28.62% in 2022, then soared by 34 bps to 38.47% in 2023, then tumbled by 33 bps to 25.9% in 2024, then grew by 15 bps to 29.72% in 2025, then grew by 2 bps to 30.3% in 2026.
• The last three EBT Margin figures came in at 30.3% (Q1 2026), 29.72% (Q4 2025), and 36.71% (Q3 2025), per Business Quant data.